Loading stock data…
Talphera, Inc. (TLPH)
$1.19-0.01 (-0.83%)
Market ClosedLast close Sep 8
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Talphera, Inc. in the Healthcare sector is trading at $1.19 with a market capitalization of $62M. Wall Street consensus targets $3.17 (3 analysts), implying a +166.1% move over the next 12 months. The stock is currently 24% below its 52-week high of $1.57, remaining 16.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +166.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $1,000 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.92M↑ | -$3.95M↓ | -$3.45M↓ | -$3.42M↑ | -$3.69M |
| Net Income | -$4.31M↓ | -$2.56M↑ | -$3.77M↑ | -$4.44M↓ | -$3.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$61.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-104.65%
Volume
Today's trading volume
151,371
Recent News
Talphera (TLPH) Q2 2026 Earnings Call Transcript
NEPHRO study hits 75% enrollment with data expected by year-end.
Talphera, Inc. Q2 2026 Earnings Call Summary
Moby summary of Talphera, Inc.'s Q2 2026 earnings call
Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ...
Talphera Inc (TLPH) reports $17.1M cash balance and advances toward Niyad PMA filing in H1 2027, backed by updated market research showing 200,000 annual CRRT procedures.
Talphera Q2 Earnings Call Highlights
Talphera (NASDAQ:TLPH) said it had reached 75% enrollment in its NEPHRO-CRRT registrational study and remains on track to complete enrollment later in 2026, as the company prepares for a potential commercial launch of its nafamostat anticoagulant candidate for continuous renal replacement therapy, o
Talphera, Inc. Q1 2026 Earnings Call Summary
Moby summary of Talphera, Inc.'s Q1 2026 earnings call